Summary.-Ten xenograft lines of human colonic and rectal carcinomas have been established in immune-suppressed mice. Mice bearing tumours in the 2nd to 6th passage were treated with maximum tolerated doses of 8 chemotherapeutic agents and tumour growth delay was estimated in terms of the number of volume doubling times gained by the treatment. The average response corresponded to a delay of only about 0-5 doubling times, but some tumour lines showed a good response to some agents. Twenty-three out of about 700 treated tumours failed to regrow. Statistical analysis showed no consistent difference in sensitivity among the tumour lines, but melphalan, 5-fluorouracil and hexamethylmelamine stood out as the most effective agents. A study of two-drug combinations showed that their order of administration had little effect on response. Only 4 of the patients who donated the xenografts were treated with chemotherapy, but among these there was some evidence that response in the xenografts correlated with response in the patient.
A QUESTION that is central to the chemotherapy of cancer is to what extent the patients within one particular histopathological disease category differ in regard to the sensitivity of their tumour cells to cytotoxic agents. Attempts have been made to test the chemosensitivity of tumour cells from individual patients, using tissue culture techniques (e.g. Berry et al., 1975) but the artificiality of the conditions of exposure and of the biological end-points has meant that the extent of variation in response has been particularly difficult to assess. As part of a wider programme of research into the therapeutic response of human tumour xenografts, we have attempted to measure the range of responses among a group of 10 different lines of colo-rectal carcinoma (numbered HXK -10), and where possible we have sought to correlate the results with the clinical response of the patients from whom the grafts were taken. This paper describes the results of this study, with emphasis on the assessment of interpatient and inter-drug variations.
MATERIALS AND METHODS
Tumnour material.-The tumour tissues used in this study were operative specimens taken from patients with adenocarcinoma of the colon or rectum (Table I) . One of the authors (K.N.) personally attended surgery in every case, and examined the tumours in situ together with the attending surgeon. Following resection of the tumour, the specimen was washed in sterile saline and a wedgeshaped sample of the growth was taken, including the invading edge. Wherever possible, specimens of liver metastases and involved lymph nodes wrere also taken. They were transported to the laboratory in icecold tissue-culture medium containing antibiotics (Eagle's basal medium (BME) plus penicillin 0-25 g/l, streptomycin 0 05 g/l, neomycin 0-1 g/l). Fragments measuring 2 mm across w-ere dissected from the most * Present ad(lress: Department of Surgery, St George's Hospital, Tooting, London SW17 OQ.J. This work forms part of an M. Phil. thesis submitted by K.N. to the University of Lon(doln. t Communications regarding this paper should be directedl to Dr Steel. viable part of the tumour specimen and implanted s.c. into recipient mice within 2 h of removal from the patient.
Immune-deprived mice.-Male and female CBA/lac mice were used, produced in the Institute of Cancer Research breeding station. At 3-4 weeks of age they were thymectomized, and 2 weeks later they were given a dose of 9 gray whole-body irradiation from a 60Co source, using a dose rate of about 0-65 gray/min. Within 2-4 h the mice received an i.v. injection of 5 x 106 syngeneic marrow cells to restore haemopoiesis. The mice were kept under non-sterile conditions in a conventional animal house, though separated from rooms containing mice used for nonxenograft work.
Tumour transplantation and measurement.-Tumour specimens were placed in chilled BME containing antibiotics, and initially cleared of necrotic tissue and fat. Pieces measuring 8 mm3 were then removed using sharp scalpels, so as far as possible to preserve uncrushed edges. The pieces used for transplantation were then picked at random and implanted s.c. over the posterior rib cage on both sides of the animal. The implants were inserted with a pair of forceps into deep subcutaneous pockets and each wound closed with a single metal clip. The mice were observed for signs of tumour growth, and shaved to allow the implants to be measured accurately. Further transplantation was carried out from tumours that had reached a volume of -2 cm3.
Growing tumours were measured every 2-3 days using plastic calipers graduated to 0-1 mm. The largest and smallest superficial dimensions were recorded, and tumour volume was calculated as n/6 (mean diameter)3. Groups of tumours were selected for chemotherapy when their average volume was 0-.0-2-0*5 cm3. Volume measurements were continued, and the interval during which each tumour increased to twice its volume at the time of treatment was found by interpolation on a semi-logarithmic plot. For each group of treated or control tumours, the median time to double (TD) was calculated and the growth delay that resulted from each treatment was defined as when given after melphalan and to 0 35 mg/kg when given before melphalan. II  III  IV  V  K2  II  III  IV  V  VI  K3  II  III  IV  K4  II  IV  K5   II  III  K6   II  III   K7   II  III   K8   II  III  K9   II  III  K1O  II   TD Tables IV, V and VI, and  Table VII shows the incidence of failures to regrow amongst the various tumourdrug combinations.
Analysis of the xenograft response to single agents Table IV are: (i) Can we say that some tumours showed significantly different response from others?
(ii) What is the ranking of the drugs against these tumours, and are their differences in effectiveness statistically significant? (iii) Is there evidence for particular tumours showing strong response to particular agents? The first two of these questions suggest an analysis of variance among the drugs and the tumour lines, and in this situation it is appropriate to use a non-parametric method. We have therefore employed Friedman's two-way analysis of variance by ranks (Siegel, 1956) When the tumour lines are ranked against the drugs (Table VIII) the probability that the sets of ranks occurred by chance on the null hypothesis of no difference among the tumour lines is 0 4. The inter-tumour differences in the ranks are therefore not significant and we must conclude that the tumour lines did not show significant differences in response to all the agents. When, however, the drugs are ranked against the tumours (Table IX) t Act D (0-35 mg/kg) was followed by melphalan at h. their effectiveness against all the tumour lines. Inspection of the rank totals shows that the scores for melphalan, HMM and 5FU were considerably lower than for the other 4 drugs, and therefore there are grounds for concluding that these 3 agents were significantly more effective than the others. These were the 3 agents that also rank best in terms of the number of tumour lines that gave a growth delay in excess of 1-0 (Table IV) . as a fraction of the number of tumours whose size was followed. x2=7-6 (7 d.f.). P=0.4. * By the Friedman 2-way analysis of variance by ranks (Siegel, 1956) . Low ranks indicate good response. P=0.05. * By the Friedman 2-way analysis of variance by ranks (Siegel, 1956) . Low ranks indicate good response.
Although there does appear to be of drugs, there was evidence for the specific evidence for significant differences in drug sensitivity of a given tumour to one or effectiveness, it should not be overlooked more particular drugs. that the less effective agents did give good responses with some tumour lines ( Tables  V and VI , each combination gave a good proportion of responses in excess of 1-0 doubling times. In KI and K5 treated with 5FU and melphalan, there were treatment groups in which more than half the tumours failed to regrowduring the course of the experiment. In these groups it is not possible to obtain the median growth delay, so a minimum value is given instead. It can be seen that these median values show no obvious trend in favour of one combination over another and the grand median values for each combination against all the tumour lines are similar. Clinical response of the patients Of the 10 patients from whom xenograft lines were established, 4 were treated with cytotoxic drugs but subsequently died. The remaining 6 received no treatment other than surgery and 2 of these patients are alive and well. The patients who received chemotherapy were the donors of xenografts KI, K3, K9 and Kio.
K1 patient
During an operation for right hemicolectomy the liver of this patient was found to contain multiple metastases. On abdominal examination, the edge of the liver could be palpated below the right costal margin, and ultrasonography confirmed the presence of multiple lesions. The serum carcinoembryonic antigen (CEA) level was elevated (62 ng/ml). The course of treatment consisted of MeCCNU (150 mg/M2 on Day 1), 5FU (325 mg/M2 i.v. daily for 5 consecutive doses), and imidazole carboxamide (75 mg/M2 i.v. daily for 5 consecutive doses). Eight courses of treatment were given over a period of 11 months.
About 2 months after the start of treatment, the condition of the patient improved, she began to gain weight and the serum CEA level fell. The liver was no longer palpable and the ultrasound scan showed no progression of the disease. In spite of continued treatment, 5 months later the patient's condition deteriorated and she died, having survived 14 months from diagnosis.
K3 patient
This patient had a palliative right hemicolectomy. The liver was enlarged and multiple liver metastases were found; the serum CEA level was 480 ng/ml. This patient received 4 courses of chemotherapy (as for patient K1) but this was discontinued when it became evident that he was not responding. The survival time from diagnosis was 13 months.
K9 and K1O patients
Both these patients had rapidly progressing disease. There was no evidence of response to chemotherapy and they died having received only one and 3 courses of treatment respectively.
DISCUSSION
General conclusions on the ranking of the anti-tumour agents
The statistical test that is summarized in Table IX has shown that, when the drugs are ranked in terms of the response achieved with all the 8 tumour lines that could be assessed, the differences in response were just significant at the 0.05 level. Melphalan, 5FU and HMM stood out as being the most effective agents. However, inspection of the median growth delays shown in Table IV shows that differences among the drugs were not large, and that good responses (defined as growth delays > 10 volumedoubling time) were scattered among almost all the drugs and tumour lines.
Although it would take multiple repeats of the experiments to confirm that these good responses did not occur by chance, the results suggest that each tumour line had its own spectrum of drug response, and that the drug giving a good response was not always the same. For instance, actinomycin D and MTX, although they ranked poorest overall, nevertheless achieved a very good response in K5. The data therefore support the policy of seeking to develop valid laboratory techniques by which a patient's tumour cells may be tested against a range of single agents in order to decide upon the best treatment for the individual case.
In the drug-combination experiments, we have not been able to show that the time of administration of MeCCNU in relation to a 5-day course of 5FU was important, or that the order of administration of melphalan and actinomycin D was important. Evidence that 5FU given after CCNU is less effective than when given with or before CCNU to the Lewis lung tumour has been reported by Mulder et al. (1977) . It is, however, difficult to judge to what extent this was so because when 5FU was given second it was given on Day 4 after implantation, as compared with Day 2 or 3 for the other groups.
Evidence for the influence of host resistance on tumour response
In the previous study in this laboratory by Kopper and Steel (1975) Table VII , there were altogether 23 tumour implants that failed to regrow to the treatment size within the duration of the experiment. These occurred in 7 of the 10 tumour lines, but the bulk of the failures to regrow occurred in response to 5FU, MeCCNU and melphalan. These ''cures" occurred amongst a group of tumours whose overall median growth delay was 0 51 doubling times. Although it is dangerous to try to infer the level of clonogenic-cell kill from an average growth delay (McNally, 1973; Steel and Adams, 1975) , it is difficult to believe that a 0-5 doubling time growth delay was associated with as much as 9000 cell kill in most of the tumours.
During the course of these experiments, parallel work in this laboratory has identified ways of improving the level of immune suppression of thymectomized 583q mice (Steel et al., 1978) and by means of cell titration tests it has been shown that mice thus suppressed may be more receptive to transplantation than congenitally athymic (nude) mice. Whilst confirming the importance of host resistance against xenografts, this work indicates that it can be manipulated.
Relationship between the response of the xenografts and the clinical response of the patients
The comparison of the response of the xenografts and the response of the patients to chemotherapy was one objective of the present work, but the results are inconclusive. Colorectal carcinomas were selected because of the likelihood that 8 or more tumour lines might be established within a period of about 12 months. We were fully aware that not all the patients would eventually be given chemotherapy, and that assessment of response would be difficult. In the event, only 4 patients received chemotherapy. One responded well, while the other 3 did not respond to drug treatment. Their treatment was based upon 5FU and MeCCNU, and it is significant that the xenografts from the patient who did well (Ki ) ranked highest of all the tumours against MeCCNU and ranked second highest against 5FU. Furthermore, in the tests of combinations of 5FU and MeCCNU (Table V) , KI was the most responsive ofthe 10 tumour lines examined. Although it is disappointing that in only 1 of these 10 cases could the patient's response to chemotherapy be objectively assessed, it is nevertheless remarkable that her clinical response was good in comparison with other colonic carcinoma patients treated on this schedule, and that the response of her tumour xenografts was the best of the 10 lines that we have studied.
Carcinoma of the colon and rectum is a disease that does not respond well to existing chemotherapy. The xenograft responses are broadly in line with this, with an average overall growth delay of less than one volume-doubling time. Perhaps the most important result of the present study is the evidence that individual tumour lines responded best to different agents, thus supporting the need to develop tests of tumour-cell chemosensitivity that may influence the choice of drugs for each patient, and allow the unnecessary treatment of patients with unresponsive tumours to be avoided.
